Hwang Jeong Ah, Kang Tae Wook, Min Ji Hye, Kim Young Kon, Kim Seong Hyun, Sinn Dong Hyun, Kim Kyunga
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Eur J Radiol. 2022 Jun;151:110328. doi: 10.1016/j.ejrad.2022.110328. Epub 2022 Apr 22.
The role of computed tomography (CT)/magnetic resonance imaging (MRI) surveillance for hepatocellular carcinoma (HCC) is unclear. We aimed to determine whether the intensity of imaging surveillance using CT and MRI is associated with tumor stage at diagnosis or survival in patients with HCC.
This retrospective cohort study included 529 patients with newly diagnosed HCC under regular surveillance (twice a year testing) at a tertiary academic center. All patients were divided into a standard surveillance group (n = 62; ultrasonography [US] with alpha-fetoprotein) and an intensive imaging surveillance group (US and CT/MRI with alpha-fetoprotein); the latter was divided into a low- (n = 232) and high-intensive (n = 235) imaging surveillance group based on the median percentage of CT/MRI investigations (cut-off, 27%). Relationship between surveillance imaging, stage of HCC at diagnosis, and overall survival (OS) were analyzed.
The low- and high-intensive imaging surveillance groups (odds ratio [OR], 0.44; 95% confidence interval [CI], 0.20-0.95; p = 0.034 and OR, 0.40; 95% CI, 0.19-0.86; p = 0.014, respectively) had better performances than the standard surveillance group to detect very early-stage HCC. OS was associated with albumin-bilirubin grade (hazard ratio [HR], 1.98; 95% CI, 1.28-3.07; p < 0.001 for grade 2 and HR, 3.03; 95% CI, 1.11-8.30; p = 0.027 for grade 3) and the applicability of curative treatment (HR, 2.34; 95% CI, 1.63-3.36; p < 0.001). However, surveillance intensity did not affect OS (p > 0.05).
Imaging surveillance for HCC using alternative CT/MRI in addition to US compared to standard practice of US only facilitates the diagnosis of very early-stage HCC but may not improve OS.
计算机断层扫描(CT)/磁共振成像(MRI)监测在肝细胞癌(HCC)中的作用尚不清楚。我们旨在确定使用CT和MRI进行成像监测的强度是否与HCC患者诊断时的肿瘤分期或生存率相关。
这项回顾性队列研究纳入了在一家三级学术中心接受定期监测(每年两次检测)的529例新诊断的HCC患者。所有患者被分为标准监测组(n = 62;超声[US]联合甲胎蛋白)和强化成像监测组(US联合CT/MRI及甲胎蛋白);后者根据CT/MRI检查的中位百分比(临界值为27%)分为低强度(n = 232)和高强度(n = 235)成像监测组。分析监测成像、诊断时HCC分期与总生存期(OS)之间的关系。
低强度和高强度成像监测组(优势比[OR]分别为0.44;95%置信区间[CI]为0.20 - 0.95;p = 0.034和OR为0.40;95% CI为0.19 - 0.86;p = 0.014)在检测极早期HCC方面的表现优于标准监测组。OS与白蛋白-胆红素分级(风险比[HR],1.98;95% CI为1.28 - 3.07;2级时p < 0.001,3级时HR为3.03;95% CI为1.11 - 8.30;p = 0.027)以及根治性治疗的适用性(HR,2.34;95% CI为1.63 - 3.36;p < 0.001)相关。然而,监测强度并未影响OS(p > 0.05)。
与仅采用US的标准做法相比,除US外使用替代CT/MRI对HCC进行成像监测有助于极早期HCC的诊断,但可能无法改善OS。